Cargando…
Circular RNA circSMARCA5 is a prognostic biomarker in patients with malignant tumor: a meta-analysis
BACKGROUND: Malignant tumor is one of the most serious diseases endangering human health. Circular RNAs play an important role in the tumorigenesis and progression of various malignant tumors. Although various studies have investigated the biological function of circular RNA circSMARCA5 in malignant...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8145840/ https://www.ncbi.nlm.nih.gov/pubmed/34034688 http://dx.doi.org/10.1186/s12885-021-08316-3 |
_version_ | 1783697262194458624 |
---|---|
author | Chao, Fan Wang, Shiyu Zhang, Cong Han, Dunsheng Ma, Zhe Chen, Gang |
author_facet | Chao, Fan Wang, Shiyu Zhang, Cong Han, Dunsheng Ma, Zhe Chen, Gang |
author_sort | Chao, Fan |
collection | PubMed |
description | BACKGROUND: Malignant tumor is one of the most serious diseases endangering human health. Circular RNAs play an important role in the tumorigenesis and progression of various malignant tumors. Although various studies have investigated the biological function of circular RNA circSMARCA5 in malignant tumors, the prognostic value of circSMARCA5 in malignant tumor patients has not been systematically analyzed. METHODS: Relevant studies were obtained from the PubMed and Web of Science database. The quality of the enrolled studies was evaluated using the Newcastle-Ottawa Scale quality assessment system. Survival features and clinicopathological features were assessed using pooled hazard ratios and odds ratios with 95% confidence intervals, respectively. RESULTS: Overall, 7 relevant publications were enrolled in the meta-analysis. CircSMARCA5 expression was significantly correlated with better OS (HR = 0.51, 95%CI 0.41–0.65) or DFS/RFS/PFS (HR = 0.56, 95%CI 0.43–0.73) in malignant tumors. In the pooled analyses of clinicopathological characteristics, malignant tumors with higher circSMARCA5 were better differentiated (OR = 0.41, 95%CI 0.19–0.88). CircSMARCA5 expression was correlated with less advanced TNM stage (OR = 0.33, 95%CI 0.19–0.55). Moreover, malignant tumors with higher circSMARCA5 expression have less advanced lymph node metastasis (OR = 0.26, 95%CI 0.08–0.79). CONCLUSION: These results indicated that circSMARCA5 was a promising biomarker in malignant tumors, which may potentially facilitate clinical decisions in the future. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-021-08316-3. |
format | Online Article Text |
id | pubmed-8145840 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-81458402021-05-25 Circular RNA circSMARCA5 is a prognostic biomarker in patients with malignant tumor: a meta-analysis Chao, Fan Wang, Shiyu Zhang, Cong Han, Dunsheng Ma, Zhe Chen, Gang BMC Cancer Research Article BACKGROUND: Malignant tumor is one of the most serious diseases endangering human health. Circular RNAs play an important role in the tumorigenesis and progression of various malignant tumors. Although various studies have investigated the biological function of circular RNA circSMARCA5 in malignant tumors, the prognostic value of circSMARCA5 in malignant tumor patients has not been systematically analyzed. METHODS: Relevant studies were obtained from the PubMed and Web of Science database. The quality of the enrolled studies was evaluated using the Newcastle-Ottawa Scale quality assessment system. Survival features and clinicopathological features were assessed using pooled hazard ratios and odds ratios with 95% confidence intervals, respectively. RESULTS: Overall, 7 relevant publications were enrolled in the meta-analysis. CircSMARCA5 expression was significantly correlated with better OS (HR = 0.51, 95%CI 0.41–0.65) or DFS/RFS/PFS (HR = 0.56, 95%CI 0.43–0.73) in malignant tumors. In the pooled analyses of clinicopathological characteristics, malignant tumors with higher circSMARCA5 were better differentiated (OR = 0.41, 95%CI 0.19–0.88). CircSMARCA5 expression was correlated with less advanced TNM stage (OR = 0.33, 95%CI 0.19–0.55). Moreover, malignant tumors with higher circSMARCA5 expression have less advanced lymph node metastasis (OR = 0.26, 95%CI 0.08–0.79). CONCLUSION: These results indicated that circSMARCA5 was a promising biomarker in malignant tumors, which may potentially facilitate clinical decisions in the future. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-021-08316-3. BioMed Central 2021-05-25 /pmc/articles/PMC8145840/ /pubmed/34034688 http://dx.doi.org/10.1186/s12885-021-08316-3 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Chao, Fan Wang, Shiyu Zhang, Cong Han, Dunsheng Ma, Zhe Chen, Gang Circular RNA circSMARCA5 is a prognostic biomarker in patients with malignant tumor: a meta-analysis |
title | Circular RNA circSMARCA5 is a prognostic biomarker in patients with malignant tumor: a meta-analysis |
title_full | Circular RNA circSMARCA5 is a prognostic biomarker in patients with malignant tumor: a meta-analysis |
title_fullStr | Circular RNA circSMARCA5 is a prognostic biomarker in patients with malignant tumor: a meta-analysis |
title_full_unstemmed | Circular RNA circSMARCA5 is a prognostic biomarker in patients with malignant tumor: a meta-analysis |
title_short | Circular RNA circSMARCA5 is a prognostic biomarker in patients with malignant tumor: a meta-analysis |
title_sort | circular rna circsmarca5 is a prognostic biomarker in patients with malignant tumor: a meta-analysis |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8145840/ https://www.ncbi.nlm.nih.gov/pubmed/34034688 http://dx.doi.org/10.1186/s12885-021-08316-3 |
work_keys_str_mv | AT chaofan circularrnacircsmarca5isaprognosticbiomarkerinpatientswithmalignanttumorametaanalysis AT wangshiyu circularrnacircsmarca5isaprognosticbiomarkerinpatientswithmalignanttumorametaanalysis AT zhangcong circularrnacircsmarca5isaprognosticbiomarkerinpatientswithmalignanttumorametaanalysis AT handunsheng circularrnacircsmarca5isaprognosticbiomarkerinpatientswithmalignanttumorametaanalysis AT mazhe circularrnacircsmarca5isaprognosticbiomarkerinpatientswithmalignanttumorametaanalysis AT chengang circularrnacircsmarca5isaprognosticbiomarkerinpatientswithmalignanttumorametaanalysis |